In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 501–600 of 673
Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1
Qian, L., Ni, R., Lv, P., Chai, Y., Awadasseid, A., Xiong, X., & Zhang, W. (2026) · ChemMedChem · doi:10.1002/cmdc.202500972 · Cited by 6
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M. M., Helyes, Z., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R., Patel, H. H., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70376 · Cited by 5
“Fc-mediated T cells and further increase the antibody's effect on tumour burden (Arlauckas et al., 2017; Dahan et al., 2015).”
Roudi, R., Beikzadeh, B., Beikzadeh, B., Kalantari, S., & Sobhani, N. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03676-9 · Cited by 9
Glazer, S. E., Sutton, M. N., Yang, P., Pisaneschi, F., Sebastian, M. M., Gammon, S. T., & Piwnica-Worms, D. (2026) · Theranostics · doi:10.7150/thno.123285 · Cited by 5
“…of human 4Ig-B7-H3 in 4T1 tumors significantly increased tumor-specific retention of 89 Zr-DFO-MIL33B in vivo relative to isotype control, and CDR-specific binding to the tumor compartment in a highly immune infiltrated environment, replete with Fc γ R expression and internalizing MDSCs [63, 65].”
Zheng, Y., Zhu, J., Xiong, J., Jiang, O., Wang, H., Xie, Y., Zhou, Y., & Xu, N. (2024) · Cancer · doi:10.1002/cncr.35259 · Cited by 6
“13 In addition, the fragment crystallizable (Fc) domain also compromises their antitumor activity by interacting with Fc γ receptors.”
BackgroundEmerging insights into intravital imaging, unraveling its role in cancer immunotherapy
Yang, M., Hou, S., Chen, Y., Chen, H., Chu, M., & Liu, S. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03944-1 · Cited by 6
“…Monitoring of the interaction between DCs and T cells [42] DPE-GFP TAMs-mediated resistance pathway in anti-PD-1 immunotherapy [43] Ccr2 − / − mice Immunosuppressive behavior of Ly6Clo monocytes [15] C57BL/6-Tg (CAG-EGFP) 1Osb/J Observation of antigen-containing microparticles…”
Intravital Imaging of Immune Responses in the Cancer Microenvironment
Hirao, H., Honda, M., Tomita, M., Li, L., Adawy, A., Xue, W., & Hibi, T. (2025) · Cancer Medicine · doi:10.1002/cam4.70899 · Cited by 5
Pu, L., Zhang, X., Cheng, P., & Sun, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638445 · Cited by 8
Tang, Y., Xu, Z., Ye, Z., Li, S., & Zhou, Q. (2023) · Head & Neck · doi:10.1002/hed.27544 · Cited by 7
“18 21 In addition, a phase 3 clinical trial, RATIONALE-309 uncovers that this immune checkpoint inhibitor outperforms ongoing first-line treatment (gemcitabine-cisplatin chemotherapy) in patient survival.”
BackgroundYadigaroglu, K., Scharf, S., Gretser, S., Schäfer, H., Deli, A. S. S., Loth, A. G., Yegoryan, H., Schmitz, R., Donnadieu, E., Hansmann, M., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284512 · Cited by 7
“37 In conclusion, nivolumab altered cell-cell interactions be-tween CD4 + T cells and CD30 + HRS cells in cHL.”
BackgroundHost-dependent variables: The missing link to personalized medicine
Demlová, R., Dubská, L. Z., Štěrba, J., Stanta, G., & Valík, D. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.04.014 · Cited by 5
Xia, L. P., Zhang, H., Bao, J., Zhao, Y.-C., & Xia, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706865 · Cited by 5
“Although the antibody-dependent cellular phagocytosis (ADCP) of the immunoglobulin G4 (IgG4) antibody is weaker than those of the IgG1 and IgG3 antibodies, it still retains some of the ADCP effect, which may affect the ability of T cells to kill tumor cells, thereby affecting the antitumor efficacy of anti-PD-1 monocl…”
BackgroundTsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5
Qu, F., Wu, S., & Zhang, J. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001241 · Cited by 5
Zhao, C., Liu, F., Dong, J., Du, C., Zhang, C., Wang, C., Zhang, X., Zhou, Q., Liu, W., Yang, A., et al. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23923 · Cited by 5
Kakiuchi, Y., Saruwatari, K., Tokito, T., Iriki, T., Iwakawa, J., Sakata, Y., Shingu, N., Saeki, S., Inaba, M., Takaki, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108578 · Cited by 4
Zhang, W., Yang, T., Jin, T., Zhu, T., Fang, H., Fan, M., & Zhang, Y. (2025) · Advanced Science · doi:10.1002/advs.202506409 · Cited by 4
Remaily, B. C., Young, G., Lathrop, H., Thomas, J., Kim, K., Vu, T. T., Adeluola, A., Stanton, C., Mulcahy, G., Xie, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1669979 · Cited by 4
Huang, C., Phann, T. T., Ouyang, F., Zhou, D., Guo, P., Wang, Y., Huang, Y., Zeng, T., Gao, Q. S., Wei, H. Z., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04167-x · Cited by 4
“However, monoclonal antibodies have been reported to bind to Fcγ receptors (FcγRs) expressed on host myeloid cells via their Fc domains and be subsequently captured by tumor-infiltrating macrophages within minutes, which impairs their therapeutic efficacy [19].”
Ono, K., & Momen‐Heravi, F. (2026) · Cancers · doi:10.3390/cancers18091410 · Cited by 5
“Blocking Fc γ receptors prolonged anti-PD-1 binding to CD8 T cells and enhanced tumor regression in mice [15].”
Martin, S., Wendlinger, L., Zitti, B., Hicham, M., Postupalenko, V. Y., Marx, L., Attianese, G. M. P. G., Cribioli, E., Irving, M. B., Litvinenko, A., et al. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01142-1 · Cited by 4
“…additional effects such as the efficient capture of the radiolabeled antibody by tumor associated macrophages via Fcg receptors and its subsequent retention in this cell population is also a possible mechanism contributing to the high CXCR3 independent tumor uptake of [ 64 Cu] Cu-NOTA-α-CXCR3 [33].”
BackgroundRaghavan, S., Shifrin, N. T., Kochel, C. M., Sawant, A., Mello, M., Sathe, M., Blumenschein, W. M., Muise, E. S., Chackerian, A. A., Pinheiro, E. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752348 · Cited by 5
“Macrophages were demonstrated to capture and remove the PD1Ab bound on CD8 T cells through FcgRIIB/III interactions making the PD-1 on the CD8 T cells, now sensitive to the interaction with PD-L1 and partial tumor regression (6).”
BackgroundRecent Developments in the Study of the Microenvironment of Cancer and Drug Delivery
Chaudhary, B., Kumar, P., Arya, P., Singla, D., Kumar, V., Kumar, D., Roshan, S., Wadhwa, S., Gulati, M., Singh, S. K., et al. (2022) · Current Drug Metabolism · doi:10.2174/1389200224666230110145513 · Cited by 5
In vivo visualization of immunosuppressive cells in the tumor microenvironment
Bao, G., Zhou, J., Cheng, S., Zhao, J., & Zhu, X. (2023) · iRadiology · doi:10.1002/ird3.33 · Cited by 4
Wang, K., Xiang, Y., Yu, H., Cheng, Y., Feng, J.-K., Liu, Z., Shan, Y., Zheng, Y., Ni, Q., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11485-y · Cited by 4
Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity
Farhat-Younis, L., Na, M., Zarfin, A., Khateeb, A., Santana-Magal, N., Richter, A., Gutwillig, A., Rasoulouniriana, D., Gleiberman, A., Beck, L., et al. (2024) · eLife · doi:10.7554/elife.91999 · Cited by 4
Villanueva, M. T. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.47 · Cited by 4
An, C., & Chen, W. (2021) · Biophysics Reports · doi:10.52601/bpr.2021.210022 · Cited by 4
“More importantly, in the following circumstances: (1) potential capture of monoclonal antibodies by Fcγ receptors expressed on myeloid cells (An et al. 2020; Arlauckas et al. 2017) (Fig.”
Macrophages hijack anti-PD-1 therapy
Killock, D. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.79 · Cited by 4
Zhang, C., Adusei, M., Baranovic, A., DeBenedetto, M., Lauricella, A., Chilel-Martin, S., Newsom-Stewart, C. M., Schwartz, J., & Kurt, R. A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103929 · Cited by 5
Buj, R., Cole, A. R., Danielson, J., Xu, J. P., Hurd, D. E., Kishore, A., Kedziora, K. M., Chen, J., Yang, B., Barras, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.637227 · Cited by 8
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
Hock, B. D., Goddard, L., Dobson, L. J., MacPherson, S. A., O'Donnell, J. L., McKenzie, J. L., & McLellan, A. D. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04078-0 · Cited by 4
“Fc-mediated signalling has been shown to modulate the anti-tumour activity of anti-PD-1/PD-L1 mAbs [3, 5–10] and therefore understanding the Fc-mediated signals delivered following binding of these antibodies is critical to optimising their use.”
Armero, M., Smolkin, M., García‐Domínguez, M., Berraondo, P., Melero, I., & Gálvez‐Cancino, F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0434 · Cited by 3
Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives
Gu, Q., Li, S., Hou, S., Liu, J., Zhang, X., Xi, Y., Chen, H., Liu, S., Chu, M., & Yang, M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08020-5 · Cited by 4
“For instance, this imaging technique can be coupled with other modalities, such as dynamic in situ cytometry (DISC), which utilizes cell surface labeling to correlate phenotypic markers with motility parameters [44].”
InfluentialRohrberg, K. S., Melero, I., Sanmamed, M. F., Muñoz‐Couselo, E., Cervantes, A. M. R., Gambardella, V., Greillier, L., Garrido, P., Kim, H. R., Lee, D. H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012729 · Cited by 3
Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma
Lossos, C., Liu, Y., Christie, A. L., Hemann, M. T., & Weinstock, D. M. (2016) · Blood · doi:10.1182/blood.v128.22.47.47 · Cited by 3
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity
Baecher, K. M., & Ford, M. L. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03004-4 · Cited by 3
“demonstrated in a murine model that macrophages are able to remove anti-PD-1 from the cell surfaces of T cells in an FcγR-dependent manner, and furthermore that upon FcγRIIB/III blockade prior to anti-PD-1 administration there was prolonged interaction between the drug and the target tumor-infiltrating CD8 + T cells a…”
Chang, M., Ellmaker, K., Esposito, A., Lauricella, A., Pa, S., Roberts, M., & Kurt, R. A. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2252463 · Cited by 3
“…show a high number of TAM correlate with poor prognosis, and negatively impact efficacy of checkpoint inhibitor therapy in patients with cancer (Arlauckas et al., 2017; Cassetta & Kitamura, 2018; Gollapudi et al., 2013; Gwak et al., 2015; Illemann et al., 2014; Santoni et al., 2018; Yuan et…”
Cheng, Y., Hu, L., Yu, Q., Ren, Y., Zhang, M., Gao, L., Lyu, S., Wang, J., Xiao, E., Chen, Z., et al. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1469568 · Cited by 3
Zhao, J., Zhang, K., Sui, D., Wang, S., Li, Y., Tang, X., Liu, X., Song, Y., & Deng, Y. (2024) · Nanoscale · doi:10.1039/d4nr01740d · Cited by 3
Indicators of a pro-tumor immune response are evident at early stages of breast cancer
Zhang, C., & Kurt, R. A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02368-w · Cited by 3
Tissue-engineered 3D cancer microenvironment for screening therapeutics
Li, N. T., Co, I. L., Landon‐Brace, N., Latour, S., & McGuigan, A. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818128-7.00019-8 · Cited by 7
Ferrara, R., Ricciuti, B., Ambrogio, C., & Trapani, D. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.001 · Cited by 5
Nishibori, S., Takeda, Y., Igase, M., & Mizuno, T. (2025) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2025.111000 · Cited by 2
Multimodality mapping of immunotherapy distribution as a predictive marker in glioma
Scheck, J. G., Boztepe, B., Kernbach, J. M., Jazi, K. K., Heinz, L., Schregel, K., Sturm, V. J. F., Schell, M., Bojcevski, J., Fischer, M. (., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf295 · Cited by 2
Rethinking Immune Checkpoint Inhibition in Cancer
Bakács, T., & Anderson, C. C. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70106 · Cited by 2
Tolerance to extracellular acidic pH facilitates tumor plasticity
Hasegawa, M., Xu, B., Maeda, K., Seki, M., Cai, F., Cui, R., Ando, R., Nakagawa, S., Sakamoto, A., Boycott, C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117226 · Cited by 2
“…of tumor-associated macrophages (TAMs), anti-PD-L1 can bind to the surface of TAMs—thereby limiting its availability to effector T cells 44 —we propose that complement inhibition reduces macrophage infiltration, 45 thus enhancing the delivery of anti-PD-L1 to CD8 + T cells and…”
Two-Photon Microscopy in Biological Imaging: Current Uses and Evolving Potential
Bu, Q., Gu, Y., Wang, X., Yuan, S., Song, K., & Zhang, X. (2026) · Photonics · doi:10.3390/photonics13060519 · Cited by 3
Roberts, M., Finn, J., Lass, M., Oviedo-Bermudez, E., & Kurt, R. A. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2354264 · Cited by 2
“…immune suppression (myeloid-derived suppressor cells, regulatory T cells) is needed to fully appreciate the therapeutic potential of immunotherapy (Arlauckas et al., 2017; Cassetta & Kitamur, 2018; Gwak et al., 2015; Santoni et al., 2018; Yuan et al., 2014; Zhao et al., 2017) it remains to be…”
Image-guided cancer immunotherapy
Ng, T. S. C., & Miller, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00013-9 · Cited by 2
Self-citationWang, Q., Zhang, X., Zhu, Q., Zeng, H. M., Dai, J., Chen, J., Zhao, J., Sun, G., Liu, Z., Zeng, H., et al. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04344-7 · Cited by 2
“The early recurrence observed after discontinuation of immunotherapy, regardless of tumor type, may be attributed to the cessation of PD-1/PD-L1 inhibition [26].”
Meyer, D. W., Fu, L., & Lyon, R. P. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_16 · Cited by 2
Tomiyama, T., Itoh, S., Toshida, K., Morinaga, A., Fujimoto-Kosai, Y., Tomino, T., Kurihara, T., Nagao, Y., Morita, K., Harada, N., et al. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-022-00585-4 · Cited by 2
“In addition, TAMs phagocytose PD-1 antibodies disrupt T-cell activation [17].”
BackgroundLymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow
Duval, F., & Palma, M. D. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0535 · Cited by 2
Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Moise, J., Murthy, J. J., Dabir, D., Yu, S., Kisto, F., Herron, E., & Aulakh, S. (2022) · Immuno · doi:10.3390/immuno2040041 · Cited by 2
Hagiwara, T., Numano, T., Hara, T., Sugiyama, T., Mera, Y., Tamano, S., & Miyata, H. (2022) · Journal of Toxicologic Pathology · doi:10.1293/tox.2022-0040 · Cited by 1
Ageing and its role in modulating healthy and tumour-associated macrophages
Duong, L., Jackaman, C., & Nelson, D. J. (2024) · Ageing and Cancer Research & Treatment · doi:10.37155/2972-4759-2024-02-01-1 · Cited by 1
Qing, D., Lu, Z., & Lu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1585844 · Cited by 2
Imaging of Tumor-Associated Macrophages
Khalili, N., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00763-6_91 · Cited by 1
Shin, J., Sanford, D. G., Bohm, A. A., Bachovchin, W. W., & Bullock, P. A. (2025) · Protein Expression and Purification · doi:10.1016/j.pep.2025.106876 · Cited by 1
Fc gamma receptor binding modulates IgG clearance in cancer cachexia
Remaily, B., Kim, K., Thomas, J. W., Adeluola, A. A., Young, G., Hai, M., Fukuda, M., Mulcahy, G., Stanton, C., Granchie, L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1676732 · Cited by 1
“Optimal anti-tumor ef fi cacy in anti PD-1 therapy is seen in antibodies with the least af fi nity for Fc g Rs, likely due to mitigation of Fc g R-mediated T cell depletion pathways (48, 52, 53).”
InfluentialGrape, L. M., Hanke, B., Neyazi, B., Rashidi, A., Swiatek, V. M., Schaufler, A., Dumitru, C. A., Kahlert, U. D., Croner, R. S., Mawrin, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816086 · Cited by 1
“Furthermore, TAMs modulate immunotherapy responsiveness through multiple mechanisms, including sequestration of therapeutic anti – PD-1 antibodies from T cells in CRC (54).”
Jenkins, E., Fellermeyer, M., Heraghty, D. F., Sharma, S., Mitra, T., Kotowski, M., Clarke, J., Lui, Y., Daly, S., Marin, Z., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adz4983 · Cited by 3
Lymph node fine-tuning FcγR signaling boosts anti-PD-1 therapy
Guérin, M. V., Ruggiu, M., Feldmann, L. C., Corre, B., Ombredanne, P., Iannascoli, B., Garcia, Z., Lemaître, F., Macdonald, L., Guermonprez, P., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014665 · Cited by 1
Tan, X., Fan, M., Li, Y., Wang, G., Li, H., Okoli, E. M., Shao, Y., Xu, G., & Xu, Z. (2026) · Aggregate · doi:10.1002/agt2.70410 · Cited by 1
Macrophage Plasticity in Cancer Therapy: Function, Timing, and Tradeoffs
Kovaleva, O. V., & Gratchev, A. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156916 · Cited by 1
“Arlauckas and colleagues showed by intravital imaging that anti-PD-1 antibodies were rapidly removed from PD-1-positive CD8 T cells and captured by PD-1-negative tumor-associated macrophages through Fc γ –receptor interactions [93].”
Huang, Y., Zhang, J., Tu, K., Ye, W., Zou, S., Tang, Z., & Zeng, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1881958 · Cited by 1
“TAMs can directly subvert ICB by stripping anti-PD-1 antibodies from T cells via Fc g R-mediated trogocytosis; blocking this interaction restores ef fi cacy (96) (Figure 9).”
Role of macrophages in tumor development
Karim, M. R., Hossain, D., Uddin, A. M., & Rume, F. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822368-0.00007-4 · Cited by 3
Bi, W., Xu, Z., Liu, F., Xie, Z., Liu, H., Zhu, X., Zhong, W., Zhang, P., & Tang, X. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011134 · Cited by 1
In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
Klebansky, B., Backer, M. V., Gorbatyuk, V., Vinogradova, O., & Backer, J. M. (2024) · Biomolecules · doi:10.3390/biom14050597 · Cited by 1
“…as poor diffusion and tumor permeability, irreversible binding to the first encountered antigen at the tumor periphery, and promiscuous interactions with Fc γ receptors on various cells, including tumor-associated macrophages, which “steal and sequester” antibodies from their tumor targets [7].”
BackgroundMethod for Non-covalent Functionalization of DNA Nanostructures with DNA Aptamers
Wu, Y., Park, J.-W., Lee, J., & Oh, Y. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4394-5_4 · Cited by 1
Is the "PD-L1 macrophage score" possible as an immunotherapy target in colon adenocarcinoma?
Baş, Y. (2024) · Gastrointestinal Tumors · doi:10.48130/git-0024-0004 · Cited by 1
Riller, Q., Varthaman, A., & Sibéril, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_9 · Cited by 1
Kang, C. E., Lee, S., Ahn, T., Seo, D. H., Ko, B. J., Jung, M., Lee, J., Kim, J. Y., & Kim, W. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-23311-9 · Cited by 1
Optimizing the role of immunotherapy for the treatment of glioblastoma
Cascão, R., & Faria, C. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99873-4.00012-8 · Cited by 1
Mechanisms of resistance to immunotherapy
Blauensteiner, B., Lentner, T., & Moreno‐Viedma, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00007-1 · Cited by 1
Naei, V. Y., Tubelleza, R., Monkman, J. H., Sadeghirad, H., Donovan, M. L., Blick, T., Wicher, A. Z., Bodbin, S. E., Stad, R. K., Basu, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5398442/v2 · Cited by 1
Madsen, T. D., Chen, D., Hernandez, M. O., Hammoudeh, S. M., Heydecker, M., Chen, E., Abu-Elnaj, S., Kedei, N., Wang, W., & Weigert, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.02.686127 · Cited by 1
Papers of note in Science Translational Medicine 9 (389)
Ferrarelli, L. K. (2017) · Science Signaling · doi:10.1126/scisignal.aan6297
PD-1 blockade: It’s what’s for dinner
Griffin, G. K. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan8155
REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION
Clements, D. R. (2018) · DalSpace (Dalhousie University)
The Current Status of Immunotherapy in Thoracic Malignancies
Lee, S. S., & Dy, G. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00003-2
Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies
Uhlig, J., Biggemann, L., Sheth, A. H., & Sharma, R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1721404
Calin, G., Hofman, P. M., & Mani, S. A. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-452-5
Fcγ receptors—Master regulators of antibody therapy
Beers, S. A., & Frendéus, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822028-3.00014-5
Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma
Wu, A., Jin, M. C., & Li, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819755-4.00009-6
Qin, X., Pan, L., Yan, L., Fang, Z., & Fan, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-921670/v1
Zhou, C., Yang, H., Guo, L., Cai, Q., Xi, W., Liu, J., Yuan, F., Zhang, H., Yan, C., Zhu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1556189/v1
Zhou, C., Yang, H., Guo, L., Cai, Q., Xi, W., Liu, J., Yuan, F., Zhang, H., Yan, C., Zhu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1504776/v1
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00004-5
Report from the virtual American Society of Hematology (ASH) Annual Meeting, December 5th–8th, 2020
(2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00695-4
Münz, C., & Chijioke, O. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735084294.793557461
Asara, J. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735744949.793560218
Li, Y., Liu, H., Yue, D., Chen, C., Li, C., Zhang, Z.-F., Xu, S.-Q., Lu, H., Gu, T.-T., & Wang, C. (2020) · Research Square · doi:10.21203/rs.3.rs-66234/v1
Yang, W., Zhang, M., Zhang, J., Liu, Y., Ning, J., Yang, J., Zhang, Z., Hou, L., & Chen, X. S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3986126
Tay, A. S. S., Black, K. L., & Yu, J. S. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-14732-6_4 · Cited by 1
Imaging of Tumor-Associated Macrophages
Khalili, N., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_91-1
Nakajima, T. E., Kadowaki, S., Minashi, K., Nishina, T., Yamanaka, T., Hayashi, Y., Izawa, N., Muro, K., Hironaka, S., Kajiwara, T., et al. (2023) · doi:10.1158/1078-0432.c.6530139.v1
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926.v1
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.